Kathryn M Wilson1, Irene M Shui1, Lorelei A Mucci1, Edward Giovannucci1. 1. From the Departments of Epidemiology (KMW, IMS, LAM, and EG) and Nutrition (EG), Harvard School of Public Health, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, and Harvard Medical School, Boston, MA (KMW, LAM, and EG).
Abstract
BACKGROUND: High calcium intake has been associated with an increased risk of advanced-stage and high-grade prostate cancer. Several studies have found a positive association between phosphorus intake and prostate cancer risk. OBJECTIVE: We investigated the joint association between calcium and phosphorus and risk of prostate cancer in the Health Professionals Follow-Up Study, with a focus on lethal and high-grade disease. DESIGN: In total, 47,885 men in the cohort reported diet data in 1986 and every 4 y thereafter. From 1986 to 2010, 5861 cases of prostate cancer were identified, including 789 lethal cancers (fatal or metastatic). We used Cox proportional hazards models to assess the association between calcium and phosphorus intake and prostate cancer, with adjustment for potential confounding. RESULTS: Calcium intakes >2000 mg/d were associated with greater risk of total prostate cancer and lethal and high-grade cancers. These associations were attenuated and no longer statistically significant when phosphorus intake was adjusted for. Phosphorus intake was associated with greater risk of total, lethal, and high-grade cancers, independent of calcium and intakes of red meat, white meat, dairy, and fish. In latency analysis, calcium and phosphorus had independent effects for different time periods between exposure and diagnosis. Calcium intake was associated with an increased risk of advanced-stage and high-grade disease 12-16 y after exposure, whereas high phosphorus was associated with increased risk of advanced-stage and high-grade disease 0-8 y after exposure. CONCLUSIONS: Phosphorus is independently associated with risk of lethal and high-grade prostate cancer. Calcium may not have a strong independent effect on prostate cancer risk except with long latency periods.
BACKGROUND: High calcium intake has been associated with an increased risk of advanced-stage and high-grade prostate cancer. Several studies have found a positive association between phosphorus intake and prostate cancer risk. OBJECTIVE: We investigated the joint association between calcium and phosphorus and risk of prostate cancer in the Health Professionals Follow-Up Study, with a focus on lethal and high-grade disease. DESIGN: In total, 47,885 men in the cohort reported diet data in 1986 and every 4 y thereafter. From 1986 to 2010, 5861 cases of prostate cancer were identified, including 789 lethal cancers (fatal or metastatic). We used Cox proportional hazards models to assess the association between calcium and phosphorus intake and prostate cancer, with adjustment for potential confounding. RESULTS:Calcium intakes >2000 mg/d were associated with greater risk of total prostate cancer and lethal and high-grade cancers. These associations were attenuated and no longer statistically significant when phosphorus intake was adjusted for. Phosphorus intake was associated with greater risk of total, lethal, and high-grade cancers, independent of calcium and intakes of red meat, white meat, dairy, and fish. In latency analysis, calcium and phosphorus had independent effects for different time periods between exposure and diagnosis. Calcium intake was associated with an increased risk of advanced-stage and high-grade disease 12-16 y after exposure, whereas high phosphorus was associated with increased risk of advanced-stage and high-grade disease 0-8 y after exposure. CONCLUSIONS:Phosphorus is independently associated with risk of lethal and high-grade prostate cancer. Calcium may not have a strong independent effect on prostate cancer risk except with long latency periods.
Authors: A Berruti; L Dogliotti; G Gorzegno; M Torta; M Tampellini; M Tucci; S Cerutti; M M Frezet; M Stivanello; G Sacchetto; A Angeli Journal: Clin Chem Date: 1999-08 Impact factor: 8.327
Authors: Abraham Schneider; Linda M Kalikin; Ana C Mattos; Evan T Keller; Matthew J Allen; Kenneth J Pienta; Laurie K McCauley Journal: Endocrinology Date: 2005-01-06 Impact factor: 4.736
Authors: Lesley M Butler; Alvin S Wong; Woon-Puay Koh; Renwei Wang; Jian-Min Yuan; Mimi C Yu Journal: Cancer Res Date: 2010-06-01 Impact factor: 12.701
Authors: Alan R Kristal; Kathryn B Arnold; Marian L Neuhouser; Phyllis Goodman; Elizabeth A Platz; Demetrius Albanes; Ian M Thompson Journal: Am J Epidemiol Date: 2010-08-06 Impact factor: 4.897
Authors: Shozo Yano; R John Macleod; Naibedya Chattopadhyay; Jacob Tfelt-Hansen; Olga Kifor; Robert R Butters; Edward M Brown Journal: Bone Date: 2004-09 Impact factor: 4.398
Authors: Moritz Binder; Irene M Shui; Kathryn M Wilson; Kathryn L Penney; Lorelei A Mucci; Adam S Kibel Journal: Cancer Causes Control Date: 2015-09-25 Impact factor: 2.506
Authors: Thomas U Ahearn; Nairi Tchrakian; Kathryn M Wilson; Rosina Lis; Elizabeth Nuttall; Howard D Sesso; Massimo Loda; Edward Giovannucci; Lorelei A Mucci; Stephen Finn; Irene M Shui Journal: J Clin Endocrinol Metab Date: 2016-04-26 Impact factor: 5.958